Conduit Pharmaceuticals Inc (CDT) Stock Price, Quote & News

Company Profile

CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has stra...

Industry: Biotechnology

Sector: Healthcare

Phone: 646 491 9132

Website: www.conduitpharma.com

Address:

4581 Tamiami Trail North, Suite 200, Naples, United States

Sowalwindows Jun. 5 at 12:53 AM

$CDT I gotta feeling…. That tonight’s gonna be a good night!

0 · Reply

Gmoney2020 Jun. 4 at 11:32 PM

$CDT I wanna wake up to dollars

0 · Reply

ka1954 Jun. 4 at 8:54 PM

$CDT for once, i would like to see a short face ripping pop in this fucker

0 · Reply

Darkarts Jun. 4 at 8:02 PM

$CDT Get your shares and let her rip.

0 · Reply

Sowalwindows Jun. 4 at 7:58 PM

$CDT

0 · Reply

pakman197 Jun. 4 at 7:58 PM

$CDT

0 · Reply

Gmoney2020 Jun. 4 at 7:56 PM

$CDT $2-3

0 · Reply

Colbert9 Jun. 4 at 7:51 PM

$CDT No doubt a substantial bounce move from these levels will come; today here was probably not enough volume and not enough attention in late trading to be on the top list for possible a/h or p/m movers. But this will change for sure, either tomorrow or at the beginning of next week...

0 · Reply

Sowalwindows Jun. 4 at 6:50 PM

$CDT AH soon!!!

0 · Reply

bmakonye27 Jun. 4 at 6:09 PM

$CDT can go stupid very quickly. Gap up is big

0 · Reply

CDT Equity receives Nasdaq notice for delayed quarterly report

May 28, 2026, 4:15 PM EDT - 7 days ago

CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter

2026-05-27T14:17:57.000Z - 8 days ago

CDT Equity granted Canadian patent for AZD5904 in male infertility

AZN

May 27, 2026, 8:00 AM EDT - 8 days ago

CDT Announces Canadian Patent for AZD5904 in Male Infertility

May 7, 2026, 8:30 AM EDT - 4 weeks ago

CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market

2026-05-07T04:50:30.000Z - 4 weeks ago

CDT Equity announces AZD5904 progresses into patent cooperation treaty phase

AZN

May 6, 2026, 8:30 AM EDT - 4 weeks ago

CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions

2026-04-27T16:25:54.000Z - 5 weeks ago

CDT Equity management to meet with Maxim

2026-04-22T10:10:41.000Z - 6 weeks ago

CDT Equity files to sell 5.35M shares of common stock for holders

2026-04-20T17:25:11.000Z - 6 weeks ago

CDT Equity management to meet with Maxim

2026-04-16T12:47:10.000Z - 7 weeks ago

CDT Equity expands multi-pathway value creation strategy across pharma, IP

AZN

Apr 16, 2026, 8:30 AM EDT - 7 weeks ago

CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery

Apr 7, 2026, 8:30 AM EDT - 2 months ago

CDT Notes Sarborg Publication of PRISM Framework Expanding AI

2026-03-27T13:45:58.000Z - 2 months ago

CDT Equity Inc trading resumes

2026-03-27T13:35:40.000Z - 2 months ago

CDT Equity Inc trading halted, volatility trading pause

2026-03-26T23:50:31.000Z - 2 months ago

CDT Equity Inc trading halted, news pending

2026-03-26T13:17:06.000Z - 2 months ago

CDT Equity expands Tapinarof intellectual property portfolio with patent filings

Mar 26, 2026, 8:30 AM EDT - 2 months ago

CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings

2026-03-25T12:27:39.000Z - 2 months ago

CDT Equity announces 1-for-25 reverse stock split

Mar 25, 2026, 8:00 AM EDT - 2 months ago

CDT Equity Inc. Announces Reverse Stock Split

Mar 23, 2026, 8:30 AM EDT - 2 months ago

CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy

2026-03-18T12:46:14.000Z - 2 months ago

CDT Equity announces stockholders approved all proposals at Special Meeting

Mar 18, 2026, 8:30 AM EDT - 2 months ago

CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth

2026-03-12T12:36:57.000Z - 3 months ago

CDT Equity notes Sarborg expansion into rare disease signature intelligence

Mar 12, 2026, 8:30 AM EDT - 3 months ago

CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence

2026-03-05T13:47:10.000Z - 3 months ago

CDT Equity notes Sarborg filing of U.S. provisional patent application

Mar 5, 2026, 8:30 AM EST - 3 months ago

CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent

2026-03-04T13:38:28.000Z - 3 months ago

CDT Equity says advancing multiple initiatives to enhance shareholder value

AZN

Mar 4, 2026, 8:30 AM EST - 3 months ago

CDT Positions for Transformational Growth

2026-02-24T13:39:45.000Z - 3 months ago

CDT Equity notes Sarborg expansion into bacteria, agrochemicals

Feb 24, 2026, 8:30 AM EST - 3 months ago

CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals

2026-02-20T13:36:27.000Z - 3 months ago

CDT Equity entered into a transaction to acquire a 20% equity stake in Sarborg

Feb 20, 2026, 8:30 AM EST - 3 months ago

CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy

2026-01-30T11:11:57.000Z - 4 months ago

CDT Equity files to sell 22.85M shares of common stock for holders

2026-01-02T13:40:26.000Z - 5 months ago

CDT Equity engages NJS Foresight Bio-Advisory for out-licensing strategy

Jan 2, 2026, 8:30 AM EST - 5 months ago

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

Oct 17, 2025, 8:30 AM EDT - 8 months ago

CDT Equity Increases Bitcoin Holding

Sep 17, 2025, 8:30 AM EDT - 9 months ago

CDT Executes Cryptocurrency Treasury Reserve Strategy

Aug 26, 2025, 8:30 AM EDT - 10 months ago

CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy

Aug 5, 2025, 8:30 AM EDT - 10 months ago

Conduit to Change Name to CDT Equity Inc.

Jul 8, 2025, 8:30 AM EDT - 11 months ago

Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy

Jul 7, 2025, 8:30 AM EDT - 11 months ago

Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries

Jun 4, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health

May 22, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market

May 21, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance

May 16, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Inc. Announces Reverse Stock Split

May 9, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

May 8, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Apr 16, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Announces Leadership Changes

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

Mar 31, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904

Mar 6, 2025, 9:35 AM EST - 1 year ago

Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel

Feb 20, 2025, 8:00 AM EST - 1 year ago

Conduit Progresses Phase II of its AI Initiative with Sarborg

Feb 13, 2025, 8:00 AM EST - 1 year ago

Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model

Feb 11, 2025, 9:00 AM EST - 1 year ago

Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note

Feb 7, 2025, 8:00 AM EST - 1 year ago

Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development

Jan 28, 2025, 5:30 AM EST - 1 year ago

Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence

Dec 12, 2024, 7:30 AM EST - 1 year ago

Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics

Nov 21, 2024, 7:30 AM EST - 1 year ago

Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders

Nov 19, 2024, 4:30 PM EST - 1 year ago

Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors

Nov 4, 2024, 7:30 AM EST - 1 year ago

Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline

Nov 1, 2024, 4:45 PM EDT - 1 year ago

Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes

Aug 12, 2024, 7:00 AM EDT - 1 year ago

Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments

May 22, 2024, 7:00 AM EDT - 2 years ago

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

AZN

May 21, 2024, 8:00 AM EDT - 2 years ago

Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO

Mar 19, 2024, 7:00 AM EDT - 2 years ago

Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub

Jan 31, 2024, 8:30 AM EST - 2 years ago

Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Sowalwindows Jun. 5 at 12:53 AM

$CDT I gotta feeling…. That tonight’s gonna be a good night!

0 · Reply

Gmoney2020 Jun. 4 at 11:32 PM

$CDT I wanna wake up to dollars

0 · Reply

ka1954 Jun. 4 at 8:54 PM

$CDT for once, i would like to see a short face ripping pop in this fucker

0 · Reply

Darkarts Jun. 4 at 8:02 PM

$CDT Get your shares and let her rip.

0 · Reply

Sowalwindows Jun. 4 at 7:58 PM

$CDT

0 · Reply

pakman197 Jun. 4 at 7:58 PM

$CDT

0 · Reply

Gmoney2020 Jun. 4 at 7:56 PM

$CDT $2-3

0 · Reply

Colbert9 Jun. 4 at 7:51 PM

0 · Reply

Sowalwindows Jun. 4 at 6:50 PM

$CDT AH soon!!!

0 · Reply

bmakonye27 Jun. 4 at 6:09 PM

$CDT can go stupid very quickly. Gap up is big

0 · Reply

Sowalwindows Jun. 4 at 5:55 PM

$CDT let’s go!!

0 · Reply

Darkarts Jun. 4 at 5:32 PM

$CDT 👀

0 · Reply

pakman197 Jun. 4 at 4:39 PM

$CDT (As stated prev. in AH's).... We are a Heatin' Up!! Doop!! Please reverse this bastage.. you tricky cheatin' MMs w/ your sucker spreads... all AM.... y'all bastages!!

0 · Reply

Colbert9 Jun. 4 at 4:22 PM

$CDT Very nice day so far. Volume should continue to increase.

0 · Reply

pakman197 Jun. 4 at 3:23 PM

$CDT Reverse.. you Beotch!!

0 · Reply

Sam201 Jun. 4 at 3:22 PM

$CDT 2k more to 13 k! Next at 0.6 if it gets there.

0 · Reply

Sowalwindows Jun. 4 at 2:35 PM

$CDT be crazy not to be buying near 52 week low. When this runs it runs BIG. I have made a ton of money on this and drone tickers!

0 · Reply

ka1954 Jun. 4 at 1:43 PM

$CDT why the fuck some of u r selling at loss?

0 · Reply

ka1954 Jun. 4 at 1:35 PM

$CDT now there will no fucking buyers in sight. slow drip down

1 · Reply

TacticalTrader752 Jun. 4 at 11:24 AM

$LRHC 10 days to file 10Q or risk delisting What are these companies waiting on? $CDT is another that hasn't submitted and has until July or face the same fate

0 · Reply

pakman197 Jun. 3 at 7:57 PM

$CDT HEATING UP! IMO..... Loaded here... lets go.... show time!

1 · Reply

supplySHOCK Jun. 3 at 7:55 PM

$IVF $LBGJ $CDT there

0 · Reply

Market Cap	5.41M
Revenue (ttm)	0.00
Net Income (ttm)	-17.80M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	109,702
Avg Vol	422,744
Day's Range	N/A - N/A
Shares Out	2.93M
Stochastic %K	5%
Beta	1.93
Analysts	Strong Buy
Price Target	N/A